Nature Communications (May 2022)
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
- Ori Hassin,
- Nishanth Belugali Nataraj,
- Michal Shreberk-Shaked,
- Yael Aylon,
- Rona Yaeger,
- Giulia Fontemaggi,
- Saptaparna Mukherjee,
- Martino Maddalena,
- Adi Avioz,
- Ortal Iancu,
- Giuseppe Mallel,
- Anat Gershoni,
- Inna Grosheva,
- Ester Feldmesser,
- Shifra Ben-Dor,
- Ofra Golani,
- Ayal Hendel,
- Giovanni Blandino,
- David Kelsen,
- Yosef Yarden,
- Moshe Oren
Affiliations
- Ori Hassin
- Department of Molecular Cell Biology, Weizmann Institute of Science
- Nishanth Belugali Nataraj
- Department of Biological Regulation, Weizmann Institute of Science
- Michal Shreberk-Shaked
- Department of Molecular Cell Biology, Weizmann Institute of Science
- Yael Aylon
- Department of Molecular Cell Biology, Weizmann Institute of Science
- Rona Yaeger
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Giulia Fontemaggi
- Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute
- Saptaparna Mukherjee
- Department of Molecular Cell Biology, Weizmann Institute of Science
- Martino Maddalena
- Department of Molecular Cell Biology, Weizmann Institute of Science
- Adi Avioz
- Department of Molecular Cell Biology, Weizmann Institute of Science
- Ortal Iancu
- The Institute for Advanced Materials and Nanotechnology, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University
- Giuseppe Mallel
- Pathology Department, Curesponse Ltd
- Anat Gershoni
- Department of Molecular Cell Biology, Weizmann Institute of Science
- Inna Grosheva
- Department of Immunology, Weizmann Institute of Science
- Ester Feldmesser
- Department of Life Sciences Core Facilities, Weizmann Institute of Science
- Shifra Ben-Dor
- Department of Life Sciences Core Facilities, Weizmann Institute of Science
- Ofra Golani
- Department of Life Sciences Core Facilities, Weizmann Institute of Science
- Ayal Hendel
- The Institute for Advanced Materials and Nanotechnology, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University
- Giovanni Blandino
- Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute
- David Kelsen
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Yosef Yarden
- Department of Biological Regulation, Weizmann Institute of Science
- Moshe Oren
- Department of Molecular Cell Biology, Weizmann Institute of Science
- DOI
- https://doi.org/10.1038/s41467-022-30481-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
The differential effects of TP53 missense mutations in colorectal cancer (CRC) remain to be explored. Here the authors compare the gain of function impact of two frequent TP53 mutations in CRC and show that p53R273 mutants control a transcriptional program, which drives oncogenic signaling pathways, leading to a more aggressive phenotype and worse patient outcome.
